San Diego Life Sciences Roundup: Trius, CoDa, Zacharon, & More
09 Января 2013
The annual International CES in Las Vegas again featured a Digital Health Summit, which included a number of San Diego-based startups. Rick Valencia of Qualcomm Life posted an interesting blog here, and an end-of-year report from Rock Health showed that investments in digital health startups increased more than 44 percent in 2012, to $1.4 billion from $968 million in 2011.
09 Января 2013
CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients.
Marinus Pharmaceuticals Adds $21M Series C
07 Января 2013
Marinus Pharmaceuticals, Inc. is pleased to announce $21 million in new Series C financing from U.S. venture capital firm Domain Associates, LLC, Rusnano subsidiary RusnanoMedInvest (RMI), and co-investors.
Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.
06 Октября 2011
Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan.
Marinus Pharmaceuticals Issued Patent for Ganaxolone
29 Апреля 2011
Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid ganaxolone formulations and methods for the making and use thereof." The patent describes a novel class of small molecules to improve stability and bioavailability of nanoparticulate formulations of ganaxolone and will provide coverage until the end of 2026.
CoDa Therapeutics, Inc. announced that it has raised $19.2 million in a Series B financing.
18 Апреля 2011
San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing.
17 Апреля 2011
Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.
Анонс: Приглашаем на мастер-класс «Алгоритм диагностики и терапии дементных расстройств»
22 Марта 2024
Празднуйте здоровый сон! Всемирный день сна – 15 марта
15 Марта 2024
14 Марта 2024
Утвержден перечень критической продукции медицинской промышленности и реабилитационной индустрии
29 Марта 2024
В Новосибирске планируют осенью запустить производство препарата от оспы
29 Марта 2024
Минздрав увеличил количество индикаторов риска обращения лекарственных средств
28 Марта 2024
Российские ученые создали парентеральную и назальную противотуберкулезные вакцины
28 Марта 2024